Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases in the United States. The company is headquartered in Dublin, Ireland.
| Revenue (TTM) | $57.94M |
| Gross Profit (TTM) | $-38.73M |
| EBITDA | $-92.33M |
| Operating Margin | 50.50% |
| Return on Equity | -40.30% |
| Return on Assets | -13.80% |
| Revenue/Share (TTM) | $1.08 |
| Book Value | $5.89 |
| Price-to-Book | 1.62 |
| Price-to-Sales (TTM) | 8.90 |
| EV/Revenue | 3.211 |
| EV/EBITDA | -3.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1706.00% |
| Shares Outstanding | $52.35M |
| Float | $36.68M |
| % Insiders | 20.18% |
| % Institutions | 90.94% |
Volatility is currently contracting
Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Sarepta Therapeutics (SRPT) and Prothena (PRTA). But which of these two stocks is more attractive to value investors?
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the first quarter of 2026 and provided business highlights.
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena promoting Ms. Kingston to Chief Strategy Officer and Mr. Isaacs to General Counsel and Corporate Secretary. Mr. Malecek is departing in June.
The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
